Supplementary Figure S16



Supplementary Figure S16. Clinical response to anti-PD-1 or conventional anti-CTLA-4 is independent of FCGR2A or FCGR3A expression in patients with advanced melanoma. Pre-treatment tumor biopsies from patients with advanced melanoma were analyzed for FCGR2A and FCGR3A gene expression by bulk RNA-seq. Best overall response per RECIST 1.1 was assessed for patients treated with αPD-1 monotherapy (nivolumab or pembrolizumab), from **(a)** Gide et al., 2019 (N=41) or **(b)** Hugo et al., 2016 (N=26) datasets. Survival correlation with high (> median) or low (≤ median) **(c)** FCGR2A and **(d)** FCGR3A gene expression in pre-treatment tumor biopsies was analyzed from the Hugo et al., 2016 (N=25) dataset**.** Best overall response was also assessed for patients treated with **(e)** αCTLA-4 monotherapy (ipilimumab) from the Checkmate 067 (N=16) dataset, or the combination of αPD-1 and αCTLA-4 from the **(f)** Gide et

al., 2019 (N=31) and **(g)** Checkmate 064 and 067 (N=51) datasets. Mean Z-scores calculated from log2 scaled transcripts per million (TPM) expression counts. Data analyzed with two-way ANOVA followed by Tukey's test **(a, f, g)** or Šídák's **(b, e)** multiple comparisons test. Survival distributions compared by log-rank test with hazard ratio (HR) and confidence interval (CI) indicated **(c, d)**. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. Responders (CR or PR); Non-responders (PD).